Bio for Mark Allegretta, Ph.D. Mark Allegretta, Ph.D.Assistant Professor, Department of Pathology & Laboratory Medicine Contact Information E-mail: Mark.Allegretta@uvm.eduOffice Location: 655 Spear St. Building C Education1980 Hartwick College, Oneonta, NY, BA; Biology1990 PhD, University of Vermont, Cellular and Molecular Biology Program1990 - 1994 Stanford University, Department of Neurology, Post-doctoral training fellowResearch InterestsOur focus is on cancer biomarker discovery, assay development and validation. We study the role of the Glypican-3 (GPC3) biomarker in hepatocellular carcinoma. Additional biomarkers for colon, ovarian and breast cancer are in development, as are novel tests for somatic mutation for use as tools in genetic toxicology.Academic Appointments2000 - Present, Research Assistant Professor, Dept. of Pathology, Univ. of Vermont1998 - Present Chief Scientific Officer, BioMosaics, Inc., Burlington, VT1998 Associate Director of Immunology, InterMune Pharmaceuticals, Inc., Palo Alto, CA1994 - 1998 Scientist, Program Leader, Connetics Corporation, Palo Alto, CAAwards and Honors1994 Stanford Immunology Program Postdoctoral Fellowship1990 - 1993 National Multiple Sclerosis Society Post-doctoral Scholarship; Stanford University Publications2011 Allegretta M, Filmus J. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem. 2011 Jul 1;11(6):543-8.2009 Kandil D, Leiman G, Allegretta M, Evans M. Glypican-3 protein expression in primary and metastatic melanoma: a combined Immunohistochemistry and Immunocytochemistry study. Cancer Aug 25;117(4):271-8.2007 Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, Evans MF. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111:316-22.2006 Wang, X. Y., Degos, F., Dubois, S., Tessiore, S., Allegretta, M., Guttmann, R. D., Jothy, S., Belghiti, J., Bedossa, P., and Paradis, V. Glypican-3 expression in hepatocellular tumors: diagnostic value for pre-neoplastic lesions and hepatocellular carcinomas. Hum Pathol, :1435-1441, 2006.2005 Allegretta, M., Ardell, S. K., Sullivan, L. M., Jacobson, S., Mortreux, F., Wattel, E., and Albertini, R. J. HPRT mutations, TCR gene rearrangements and HTLV-1 integration sites define in vivo T cell clonal lineages. Environ Mol Mutagen, Mar-Apr;45 (2-3): 326-37, 2005.For a complete list of Mark Allegretta's publications, please visit PubMed.